Sept. 30–Oct. 1, 2021 • Online
- Elizabeth Budde, MD, PhD – City of Hope
- Daniel S. Chen, MD, PhD
- James L. Gulley, MD, PhD, FACP – National Cancer Institute
The safety of our attendees at our in-person events is of the utmost importance at the Society for Immunotherapy of Cancer (SITC). Given the recent increase in the COVID-19 virus and the desire to keep everyone as safe as possible, the Bispecific T cell Engagers Workshop, Sept. 30-Oct.1 2021 will now be held virtually.
SITC invites you to attend the workshop, Bispecific T cell Engagers Virtual Workshop. This workshop will focus on T cell engager biology and therapeutic strategies including target selection, therapeutic engineering and design features, cytotoxicity vs cytokine release, impact of the tumor microenvironment, and advances in conditionally-active binding.
Additionally, considerations related to dosing, schedule, sequencing and combination approaches for optimizing both endogenous and synthetic immunity will be discussed.
The virtual format assures a compelling program that can be held safely and successfully, and allows us to accommodate as many participants as possible.
To thank you for your continued interest in this workshop, we are happy to be able to offer a 50 percent discount on the registration rate. Register today at the special new rate!
- Basic, translational and clinical researchers from academic, industry, or government settings with an interest in developing, validating and applying T cell engager therapies for cancer treatment.
- Compare and contrast cancer immunotherapy approaches employing endogenous or synthetic immunity.
- Describe the biological and engineering considerations for development of T cell engagers.
- Outline current clinical application of T cell engagers and identify challenges with their use in cancer immunotherapy.